Ranitidine 

(ra nye' te deen)

PCaution when used during lactation  - Caution when used during pregnancy

LCaution when used during lactation - Caution when used during lactation

Molecule Info

|See  TERMINOLOGY & ABBREVIATIONS  |
Description

The active ingredient in Ranitidine 150 Tablets, Ranitidine 300 Tablets, and Ranitidine Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethenediamine, HCl. 
The empirical formula is C13H22N4O3SHCl, representing a molecular weight of 350.87. Ranitidine HCl is a white to pale yellow granular substance that is soluble in water. It has a slightly bitter taste and sulfur-like odor. Each Ranitidine 150 Tablet for oral administration contains 168 mg of ranitidine HCl equivalent to 150 mg of ranitidine. Each tablet also contains the inactive ingredients FD&C Yellow No. 6 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, triacetin, and yellow iron oxide.
Each Ranitidine 300 Tablet for oral administration contains 336 mg of ranitidine HCl equivalent to 300 mg of ranitidine. Each tablet also contains the inactive ingredients croscarmellose sodium, D&C Yellow No. 10 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. Each 1 mL of Ranitidine Syrup contains 16.8 mg of ranitidine HCl equivalent to 15 mg of ranitidine. Ranitidine Syrup also contains the inactive ingredients alcohol (7.5%), butylparaben, dibasic sodium phosphate, hypromellose, peppermint flavor, monobasic potassium phosphate, propylparaben, purified water, saccharin sodium, sodium chloride, and sorbitol.

Indication(s) & Usage

Ranitidine is indicated in:
1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer
for periods of more than 8 weeks.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer
than 1 year.
3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).
4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.
5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.
6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine 150 mg twice daily.

7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine 150 mg 4 times daily.
8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD and erosive esophagitis.

Dosage & Administration

Active Duodenal Ulcer:

The current recommended adult oral dosage of Ranitidine for duodenal ulcer is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice daily. An alternative dosage of 300 mg or 20 mL of syrup (4 teaspoonfuls of syrup equivalent to 300 mg of ranitidine) once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared to the other in a particular patient population have yet to be demonstrated. Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150-mg dose. Antacid should be given as needed for relief of pain.

Maintenance of Healing of Duodenal Ulcers:

The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) at bedtime.
Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice daily. In some patients it may be necessary to administer Ranitidine 150-mg doses more frequently. Dosages should be adjusted to individual patient needs, and should continue as long as clinically indicated. Dosages up to 6 g/day have been employed in patients with severe disease.

Benign Gastric Ulcer:

The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice daily.

Maintenance of Healing of Gastric Ulcers:

The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) at
bedtime.

GERD (gastroesophageal reflux disease):

The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice daily.

Erosive Esophagitis:

The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) 4 times daily.
Maintenance of Healing of Erosive Esophagitis: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine)
twice daily.

Pediatric Use

The safety and effectiveness of Ranitidine have been established in the age-group of 1 month to 16 years. There is insufficient information about the pharmacokinetics of Ranitidine in neonatal patients (younger than 1 month of age) to make dosing recommendations.

The following 3 subsections provide dosing information for each of the pediatric indications.

Treatment of Duodenal and Gastric Ulcers: The recommended oral dose for the treatment of active duodenal and gastric ulcers is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Maintenance of Healing of Duodenal and Gastric Ulcers: The recommended oral dose for the maintenance of healing of duodenal and gastric ulcers is 2 to 4 mg/kg once daily to a maximum of 150 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Treatment of GERD and Erosive Esophagitis: Although limited data exist for these conditions in pediatric patients, published literature supports a dosage of 5 to 10 mg/kg/day, usually given as 2 divided doses.

Dosage Adjustment for Patients With Impaired Renal Function

On the basis of experience with a group of subjects with severely impaired renal function treated with Ranitidine, the recommended dosage in patients with a creatinine clearance <50 mL/min is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) every 24 hours. Should the patient's condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function.

Overdosage

May lead to muscular tremors, vomiting and rapid respiration.

Contraindications

Porphyria.

Special Precautions

Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.

Adverse Drug Reaction(s)

Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.
Potentially Fatal: Anaphylaxis, hypersensitivity reactions.

Drug Interactions

Antacids may interfere with absorption. May decrease the GI absorption of ketoconazole. Smoking may decrease the plasma levels of ranitidine. May cause an increase in the bioavailability of furosemide.

Pregnancy Category (US FDA)

 Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters).

Pharmacology

Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2-receptors, including receptors on the gastric cells. Ranitidine does not lower serum Ca++ in hypercalcemic states. Ranitidine is not an anticholinergic agent. Reference Rantidine brand: ZANTAC®.

Pharmacokinetics

Absorption: Ranitidine is 50% absorbed after oral administration, compared to an intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL occurring 2 to 3 hours after a 150-mg dose. The syrup is bioequivalent to the tablets. Absorption is not significantly impaired by the administration of food or antacids. Propantheline slightly delays and increases peak blood levels of ranitidine, probably by delaying gastric emptying and transit time. In one study, simultaneous administration of high-potency antacid (150 mmol) in fasting subjects has been reported to decrease the absorption of Ranitidine.

Distribution: The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%.

Metabolism: In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to <4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%). The remainder of the administered dose is found in the stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability.

Excretion: The principal route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours. Renal clearance is about 410 mL/min, indicating active tubular excretion. The elimination half-life is 2.5 to 3 hours. Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of ranitidine intravenously had an average plasma half-life of 4.8 hours, a ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76 L/kg. In general, these parameters appear to be altered in proportion to creatinine clearance (see DOSAGE AND ADMINISTRATION).

Geriatrics: The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3 to 4 hours. Peak levels average 526 ng/mL following a 150-mg twice-daily dose and occur in about 3 hours.

Pediatrics: There are no significant differences in the pharmacokinetic parameter values for ranitidine in pediatric patients (from 1 month up to 16 years of age) and healthy adults when correction is made for body weight. The average bioavailability of ranitidine given orally to pediatric patients is 48%, which is comparable to the bioavailability of ranitidine in the adult population. All other pharmacokinetic parameter values (t1/2, Vd, and CL) are similar to those observed with intravenous ranitidine use in pediatric patients. Estimates of Cmax and Tmax are displayed in Table 1.

Table 1. Ranitidine Pharmacokinetics in Pediatric Patients Following Oral Dosing

Population (age)

n

Dosage Form (dose)

Cmax (ng/mL)

Tmax (hours)

Gastric or duodenal ulcer

(3.5 to 16 years)

12

Tablets

(1 to 2 mg/kg)

54 to 492

2.0

Otherwise healthy requiring Ranitidine

(0.7 to 14 years, Single dose)

10

Syrup

(2 mg/kg)

244

1.61

Otherwise healthy requiring Ranitidine

(0.7 to 14 years, Multiple dose)

10

Syrup

(2 mg/kg)

320

1.66

Plasma clearance measured in 2 neonatal patients (younger than 1 month of age) was considerably lower (3 mL/min/kg) than children or adults and is likely due to reduced renal function observed in this population.

Pharmacodynamics

Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94 ng/mL. Following a single oral dose of 150 mg, serum concentrations of ranitidine are in this range up to 12 hours. However, blood levels bear no consistent relationship to dose or degree of acid inhibition.

Antisecretory Activity:1. Effects on Acid Secretion: Ranitidine inhibits both daytime and nocturnal basal gastric acid secretions as well as gastric acid secretion stimulated by food, betazole, and pentagastrin, as shown in Table 2.

Table 2. Effect of Oral Ranitidine on Gastric Acid Secretion

  Time After Dose, hours % Inhibition of Gastric Acid Output by Dose, mg
75-80 100 150 200
Basal Up to 4   99 95  
Nocturnal Up to 13 95 96 92  
Betazole Up to 3   97 99  
Pentagastrin Up to 5 58 72 72 80
Meal Up to 3   73 79 95

It appears that basal-, nocturnal-, and betazole-stimulated secretions are most sensitive to inhibition by Ranitidine, responding almost completely to doses of 100 mg or less, while pentagastrin- and food-stimulated secretions are more difficult to suppress.

2. Effects on Other Gastrointestinal Secretions:

Pepsin: Oral Ranitidine does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.

Intrinsic Factor: Oral Ranitidine has no significant effect on pentagastrin-stimulated intrinsic factor secretion.

Serum Gastrin: Ranitidine has little or no effect on fasting or postprandial serum gastrin.

Other Pharmacologic Actions:

1.Gastric bacterial flora increase in nitrate-reducing organisms, significance not known.

2.Prolactin levels no effect in recommended oral or IV dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.

3.Other pituitary hormones no effect on serum gonadotropins, TSH, or GH. Possible impairment of vasopressin release.

4.No change in cortisol, aldosterone, androgen, or estrogen levels.

5.No antiandrogenic action.

6.No effect on count, motility, or morphology of sperm.

Pediatrics: Oral doses of 6 to 10 mg/kg/day in 2 or 3 divided doses maintain gastric pH >4 throughout most of the dosing interval.

Clinical Trials

Reference Rantidine brand: ZANTAC®.

Active Duodenal Ulcer: In a multicenter, double-blind, controlled, US study of endoscopically diagnosed duodenal ulcers, earlier healing was seen in the patients treated with Ranitidine as shown in Table 3.

Table 3. Duodenal Ulcer Patient Healing Rates
 

Ranitidinea

Placeboa

Number Entered

Healed/ Evaluable

Number Entered

Healed/ Evaluable

Outpatients  

Week 2

 

69/182

(38%)b

 

31/164

(19%)

 

195

 

188

 

Week 4

 

137/187

(73%)b

 

76/168

(45%)

a. All patients were permitted antacids as needed for relief of pain.

b. P<0.0001.

In these studies, patients treated with Ranitidine reported a reduction in both daytime and nocturnal pain, and they also consumed less antacid than the placebo-treated patients.

Table 4. Mean Daily Doses of Antacid
 

Ulcer Healed

Ulcer Not Healed

Ranitidine

0.06

0.71

Placebo

0.71

1.43

Foreign studies have shown that patients heal equally well with 150 mg twice daily and 300 mg at bedtime (85% versus 84%, respectively) during a usual 4-week course of therapy. If patients require extended therapy of 8 weeks, the healing rate may be higher for 150 mg twice daily as compared to 300 mg at bedtime (92% versus 87%, respectively).

Studies have been limited to short-term treatment of acute duodenal ulcer. Patients whose ulcers healed during therapy had recurrences of ulcers at the usual rates.

Maintenance Therapy in Duodenal Ulcer: Ranitidine has been found to be effective as maintenance therapy for patients following healing of acute duodenal ulcers. In 2 independent, double-blind, multicenter, controlled trials, the number of duodenal ulcers observed was significantly less in patients treated with Ranitidine (150 mg at bedtime) than in patients treated with placebo over a 12-month period.

Table 5. Duodenal Ulcer Prevalence

Double-Blind, Multicenter, Placebo-Controlled Trials

Multicenter

Trial

Drug

Duodenal Ulcer Prevalence

No. of

Patients

0-4

Months

0-8

Months

0-12

Months

 

USA

RAN

20%a

24%

35%a

138

PLC

44%

54%

59%

139

Foreign

RAN

12%a

21%a

28%a

174

PLC

56%

64%

68%

165

% = Life table estimate.

a = P<0.05 (Ranitidine versus comparator).

RAN = ranitidine (ZANTAC®).

PLC = placebo.

As with other H2-antagonists, the factors responsible for the significant reduction in the prevalence of duodenal ulcers include prevention of recurrence of ulcers, more rapid healing of ulcers that may occur during maintenance therapy, or both.

Gastric Ulcer: In a multicenter, double-blind, controlled, US study of endoscopically diagnosed gastric ulcers, earlier healing was seen in the patients treated with Ranitidine as shown in Table 6.

Table 6. Gastric Ulcer Patient Healing Rates
 

Ranitidinea

Placeboa

Number

Entered

Healed/

Evaluable

Number

Entered

Healed/

Evaluable

Outpatients

Week 2

 

16/83

(19%)

 

10/83

(12%)

 

92

 

94

 

Week 6

 

50/73

(68%)b

 

35/69

(51%)

a All patients were permitted antacids as needed for relief of pain.

P = 0.009.

In this multicenter trial, significantly more patients treated with Ranitidine became pain free during therapy.

Maintenance of Healing of Gastric Ulcers: In 2 multicenter, double-blind, randomized, placebo-controlled, 12-month trials conducted in patients whose gastric ulcers had been previously healed, Ranitidine 150 mg at bedtime was significantly more effective than placebo in maintaining healing of gastric ulcers.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): Ranitidine inhibits gastric acid secretion and reduces occurrence of diarrhea, anorexia, and pain in patients with pathological hypersecretion associated with Zollinger-Ellison syndrome, systemic mastocytosis, and other pathological hypersecretory conditions (e.g., postoperative, “short-gut” syndrome, idiopathic). Use of Ranitidine was followed by healing of ulcers in 8 of 19 (42%) patients who were intractable to previous therapy.

Gastroesophageal Reflux Disease (GERD): In 2 multicenter, double-blind, placebo-controlled, 6-week trials performed in the United States and Europe, Ranitidine 150 mg twice daily was more effective than placebo for the relief of heartburn and other symptoms associated with GERD. Ranitidine-treated patients consumed significantly less antacid than did placebo-treated patients.

The US trial indicated that Ranitidine 150 mg twice daily significantly reduced the frequency of heartburn attacks and severity of heartburn pain within 1 to 2 weeks after starting therapy. The improvement was maintained throughout the 6-week trial period. Moreover, patient response rates demonstrated that the effect on heartburn extends through both the day and night time periods.

In 2 additional US multicenter, double-blind, placebo-controlled, 2-week trials, Ranitidine 150 mg twice daily was shown to provide relief of heartburn pain within 24 hours of initiating therapy and a reduction in the frequency of severity of heartburn.

Erosive Esophagitis: In 2 multicenter, double-blind, randomized, placebo-controlled, 12-week trials performed in the United States, Ranitidine 150 mg 4 times daily was significantly more effective than placebo in healing endoscopically diagnosed erosive esophagitis and in relieving associated heartburn. The erosive esophagitis healing rates were as follows:

Table 7. Erosive Esophagitis Patient Healing Rates
 

Healed/Evaluable

Placeboa (n = 229) ZANTAC 150 mg 4 times daily(n = 215)

Week 4

43/198 (22%)

96/206 (47%)b

Week 8

63/176 (36%)

142/200 (71%)b

Week 12

92/159 (58%)

162/192 (84%)b

a All patients were permitted antacids as needed for relief of pain.

P<0.001 versus placebo.

No additional benefit in healing of esophagitis or in relief of heartburn was seen with a ranitidine dose of 300 mg 4 times daily.

Maintenance of Healing of Erosive Esophagitis: In 2 multicenter, double-blind, randomized, placebo-controlled, 48-week trials conducted in patients whose erosive esophagitis had been previously healed, Ranitidine 150 mg twice daily was significantly more effective than placebo in maintaining healing of erosive esophagitis.

ATC Classification

A02BA02 - ranitidine; Belongs to the class of H2-receptor antagonists. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

Brand Info


Total Products : 122                                                                                                                          
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
ACEPTIN-R Asiatic Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
ACIN Biopharma Laboratories Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150's, 50's: 301.50 & 175.50 MRP
ACIN Syrup Biopharma Laboratories Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 45.17 MRP
ALIN Rephco Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
ANTAC Ambee Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 181.00 MRP
ANTAC Injection Ambee Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps : 53.00 MRP
ANTAC Syrup Ambee Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 40.20 MRP
ASINAR Sanofi Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's: 201.00 MRP
BENTID-150 Benham Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 141.00 MRP
DENITINE Doctors Chemical Works Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
DETAC Desh Pharmaceuticals (Pvt) Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 40.00 MRP
DETAC-150 Desh Pharmaceuticals (Pvt) Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150's: 225.00 MRP
DUGAL Reman Drug Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's: 115.00 MRP
DURAN Techno Drugs Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's, 300mg x 100's: 200.00 & 400.00 MRP
DURAN Infusion Techno Drugs Ranitidine hydrochloride I.V Infusion 100ml: 60.00 MRP
DURAN Syrup Techno Drugs Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 40.00 MRP
E-TACK Reliance Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
EDITIN-R Edruc Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 223.00 MRP
EDITIN-R Injection Edruc Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps: 60.00 MRP
EUCON Pacific Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 190.00 MRP
EVRAN Everest Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
EXAC Hallmark Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
G-RANITIDINE Gonoshasthaya Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 143.00 MRP
GASTAB NIPRO JMI Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg usp Tablet 100's: 200.00 MRP
GASTAB Syrup NIPRO JMI Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml usp Syrup 100ml: 45.17 MRP
GASTROLOC Beacon Pharmaceuticals Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
GEPIN General Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 201.00 MRP
GEPIN Syrup General Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml, 200ml: 45.17 & 80.30 MRP
H-BLOK R A K Pharmaceuticals Pvt. Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
H2-150 Apollo Pharmaceutical Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 IP
HI-TAC Hudson Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
INRAN Monico Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps: 60.00 MRP
INRAN-150 Monico Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
INSEAC IBN SINA Pharmaceutical Industry Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x150's, 300mg x 48's: 300.00 & 192.00 IP
JOVRAN Belsen Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
LIBRET IV Libra Pharmaceuticals Ltd. Ranitidine hydrochloride I.V IV Injection 100ml: 55.21 MRP
LUMERAN Aristopharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's, 300mg x 50's: 200.00 & 175.00 MRP
MUTAC-150 Salton Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 203.00 MRP
MYSTIN-R Mystic Pharmaceuticals Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
NEOCEPTIN R 150 Beximco Pharmaceuticals Ltd Ranitidine Hydrochloride USP eq. to Ranitidine 150mg Film Coated Tablet 168's: 420.00 MRP
NEOCEPTIN R 300 Beximco Pharmaceuticals Ltd Ranitidine Hydrochloride USP eq. to Ranitidine 300mg Film Coated Tablet 100's: 400.00 MRP
NEOCEPTIN R IV Beximco Pharmaceuticals Ltd Ranitidine 0.05% w/v IV Infusion 100ml: 101.00 MRP
NEOCEPTIN R SYRUP Beximco Pharmaceuticals Ltd Ranitidine Hydrochloride USP eq. to Ranitidine 75mg/5ml Syrup 100ml: 45.00 MRP
NEOCEPTRIN R Injection Beximco Pharmaceuticals Ltd Ranitidine Hydrochloride USP eq. to Ranitidine 50mg/2ml Injection 10's: 60.00 MRP
NEOPEP Central Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
NEOSETINE-R Bristol Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
NEOSTIN-R Indo-Bangla Pharmaceuticals Works Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
NEOTACK 150 Square Pharmaceuticals Ltd. Ranitidine 150mg Tablet 10x15's: 376.50 MRP
NEOTACK 300 Square Pharmaceuticals Ltd. Ranitidine 300mg Tablet 10x10's: 451.00 MRP
NEOTACK INJ Square Pharmaceuticals Ltd. Ranitidine 50mg/2 ml IV Injection 2x5's: 100.30 MRP
NEOTACK SYP Square Pharmaceuticals Ltd. Ranitidine 75mg/5 ml Syrup 100 ml: 50.15 MRP
NEOTID Modern Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
NEOTIN Nipa Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
NORMA-H Renata Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 219.00 MRP
NORMACID Kemiko Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
NORMACID Syrup Kemiko Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 40.00 MRP
ORTAC Orion Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 201.00 MRP
ORTAC Infusion Orion Infusion Ltd. Ranitidine hydrochloride I.V Infusion 100ml: 60.00 MRP
ORTAC Injection Orion Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps: 60.20 MRP
PEOTID Peoples Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 120.00 MRP
PEPTIDLN-150 Cosmic Chemical Industries Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
PEPTIL-H Eskayef Bangladesh Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's & 150's MRP: 180.00 & 270.00
PEPTIL-H Injection Eskayef Bangladesh Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml Injection 10 amps MRP: 60.00
PEPTIL-H Syrup Eskayef Bangladesh Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml MRP: 45.00
PEPTONIL Decent Pharma Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
PEPTOSOL IV Opso Saline Ltd. Ranitidine hydrochloride I.V Injection 100ml: 35.13 MRP
RANBEX Novo Healthcare and Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
RANI Cosmo Pharma Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 202.00 MRP
RANI-150 Alco Pharma Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
RANID Ziska Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 110.00 MRP
RANID Injection Ziska Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps: 60.00 MRP
RANIDIL Millat Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
RANIDIN The Acme Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's, 150's & 100's: 201.00, 301.50 & 401.00 MRP
RANIDIN Injection The Acme Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps: 60.20 MRP
RANIDIN Syrup The Acme Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 45.16 MRP
RANIFAST S.N. Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
RANILOC Kumudini Pharma Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 225.00 MRP
RANIMIL Millat Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 202.00 MRP
RANISON Jayson Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 173.00 IP
RANISON Injection Jayson Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 10 amps: 63.10 MRP
RANISYN Syntho Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 210.00 MRP
RANIT Pharmadesh Laboratories Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
RANITAB Sonear Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 205.00 MRP
RANITACK Ad-din pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 300's: 300.00 MRP
RANITEC-150 APC Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
RANITID Opsonin Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 150's, 300mg x 100's: 300.00 & 400.00 MRP
RANITID Injection Opsonin Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 50 amps: 300.00 MRP
RANITID Syrup Opsonin Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 45.00 MRP
RANITOR Popular Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150's: 150.02 MRP
RANIX Chemist Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 75.00 MRP
RANIX Injection Chemist Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 50 amps: 50.00 MRP
RANTEC Medimet Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's, 300mg x 50's: 200.00 & 175.00 MRP
RANTIN Seema Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150's: 300.00 MRP
RANTOP Novus Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
RANUL Apex Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 100.00 MRP
RAVIA Pharmasia Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's, 150's: 100.00 & 150.00 MRP
RECODIN-150 Concord Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
REETAC-R Navana Pharmaceuticals Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's, 300mg x 50's: 201.00 & 201.00 MRP
RENETE Euro Pharma Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150's: 300.00 MRP
RENICON Medicon Laboratories Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
RHINE Healthcare Pharmacuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's MRP 250 Tk
RT 150 Silva Pharmaceuticals Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.70 MRP
SADIN Shamsul Alamin Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
SUTAC Supreme Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
TINADIN Delta Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 85.00 MRP
TINADIN Syrup Delta Pharma Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 40.00 MRP
ULCAR Drug International Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 150mg x 100's, 300mg x 50's: 200.00 & 200.00 MRP
ULCITID Marksman Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
ULTAC Aexim Pharmaceutical Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 100.00 MRP
ULTRADIN-150 Globe Pharmaceuticals Ltd Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
UNITAC Gaco Pharmaceutical Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
WINTACK The White Horse Pharma Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
XANTID ACI Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's, 150's: 201.00 & 301.50 MRP
XANTID Injection ACI Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 50mg/2ml, IM/IV Injection 2ml amp x 10's: 75.30 MRP
XANTID-HS ACI Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 402.00 MRP
XARDIN Sharif Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
ZANTAC GlaxoSmithKline Bangladesh Limited Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 405.53 MRP
ZENIDINE Zenith Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP
ZENIL Rangs Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 200.00 MRP
ZODIN Somatec Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 201.00 MRP
ZODIN Syrup Somatec Pharmaceuticals Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 75mg/5ml Syrup 100ml: 40.15 MRP
ZOREP Amico Laboratories Ltd. Ranitidine Hydrochloride USP equivalent to Ranitidine 150mg Tablet 100's: 150.00 MRP

Gen MedInfo

 

Why this medicine is needed?

Ranitidine is a gastric medicine.
It is used to treat conditions caused by excessive acidity in your stomach, such as stomach ulcers and reflux disease (also known as "heartburn", in which food or acid from your stomach backs up into your mouth, leaving a sour or bitter taste).
Ranitidine can also be used to relieve stomach irritation and ulceration caused by certain painkillers such as non-steroidal anti-inflammatory drugs (NSAIDs).
Ranitidine treats these conditions by reducing the amount of acid your stomach makes.

How to take this medicine?

Take Ranitidine exactly as directed by your doctor. Do not take more or less than instructed by your doctor.
You may need to take Ranitidine for some time before the full benefits can be felt.
Ranitidine tablets may be taken with or without food or at bedtime.
If you have been given the effervescent tablets, dissolve one tablet in a full glass (6-8 ounces) of water before drinking. Do not swallow effervescent tablets without first dissolving them in water as instructed.
Do not take Ranitidine for more than 2 weeks unless directed by your doctor. If your gastric problems persist for more than 2 weeks, consult your doctor.

What should be done if I have forgotten to take this medicine?

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your normal dosing schedule.
DO NOT double a dose under any circumstances.
Remember to take your medicine regularly. If you often forget to take your medicine, let your doctor and pharmacist know.

What should noted while taking this medicine?

Alert your doctor if you are pregnant or breastfeeding. Do not breastfeed while being treated with Ranitidine.
Alert your doctor if you have kidney or liver disease, porphyria or phenylketonuria.
Do not take Ranitidine for a long period of time unless instructed by your doctor. Let your doctor know if your gastric problem seems to be getting worse or if there is no improvement even with Ranitidine.
Do not give Ranitidine to children unless instructed by the doctor.

What side effects could appear?

Ranitidine may cause headache, constipation, diarrhoea, nausea or vomiting, stomach pain. These are usually temporary and should go away when Ranitidine is stopped.
Ranitidine may cause dizziness. If you feel dizzy, do not drive or take part in any activity in which you need to be alert.
Let your doctor know if these side effects bother you or if they do not go away.
Less commonly, Ranitidine may cause other side effects. Consult your doctor if you experience unusual problems while being treated with Ranitidine.

Can this be taken with other medicines?

Inform your doctor if you are taking any other medicines, especially those listed below:
- warfarin (a blood-thinning medicine)
- ketoconazole, itraconazole (antifungal medicines)
- cefuroxime, cefpodoxime (antibiotics)
- triazolam (mood medicine)
Do not take antacids together with Ranitidine. If you must take antacids, take them at least 1 hour before or 2 hours after you have taken Ranitidine.
Always inform your doctor and pharmacist if you are taking any other medicines, including herbal tonics, supplements and medicines that you buy without a prescription.

What special dietary instructions to follow?

Avoid alcohol.

How to store this medicine?

Store in a cool, dry place away from the reach of children. Medicines must be used within the expiry date.

 | See Brand Manufacturer's Prescribing Information | | Back to top  |